Non-small cell lung carcinoma (NSCLC) therapy has been transformed by the identification of actionable oncogenic driver mutations, of which ALK, ROS1, RET fusions and MET exon 14 skipping represent interesting drug targets [1]. This evidence concerns the gene MET and non-small cell lung carcinoma.